Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Lipids in chronic kidney disease.

Lewis D, Haynes R, Landray MJ.

J Ren Care. 2010 May;36 Suppl 1:27-33. doi: 10.1111/j.1755-6686.2010.00173.x. Review. Erratum in: J Ren Care. 2010 Sep;36(3):171. Dosage error in article text.

PMID:
20586897
2.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
3.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
4.

[Statin therapy for atherogenic hypertriglyceridemia].

Koba S.

Nihon Rinsho. 2013 Sep;71(9):1655-60. Review. Japanese.

PMID:
24205730
5.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
6.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
7.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
8.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
10.

The statin era: in search of the ideal lipid regulating agent.

Shepherd J.

Heart. 2001 Mar;85(3):259-64. No abstract available.

11.

2017 Taiwan lipid guidelines for high risk patients.

Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.

J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. Review.

12.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
13.

Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Vaziri ND, Norris KC.

Blood Purif. 2013;35(1-3):31-6. doi: 10.1159/000345176. Epub 2013 Jan 22. Review.

14.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators.

J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.

15.

Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.

Rahman M, Yang W, Akkina S, Alper A, Anderson AH, Appel LJ, He J, Raj DS, Schelling J, Strauss L, Teal V, Rader DJ; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1190-8. doi: 10.2215/CJN.09320913. Epub 2014 May 15.

16.
17.

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group.

Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2.

18.

Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Fukami K, Okuda S, Yamagishi S.

Pharmacol Res. 2010 Jan;61(1):58-61. doi: 10.1016/j.phrs.2009.07.011. Epub 2009 Aug 8.

PMID:
19666118
19.

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators.

Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.

PMID:
16214597
20.

Lipid management with statins. The lower the better?

Laufs U, Liao JK, Böhm M.

Z Kardiol. 2004 Jan;93(1):4-9. Review.

PMID:
14740235

Supplemental Content

Support Center